Behcet Disease and Vascular Involvement

2

Review clinical trials related to Behcet Disease and Vascular Involvement. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Clinical, Biochemical and Epigenetic Profile of Pediatric Behçet Disease

Behçet disease (BD) is a chronic multisystem inflammatory disorder with a relapsing-remitting course. Pediatric-onset BD is rare and characterized by marked clinical heterogeneity, frequent incomplete presentation at disease onset, and limited availability of pediatric-specific outcome measures and biomarkers. This prospective multicenter study aims to comprehensively characterize the clinical, biochemical, genetic, and epigenetic profiles of pediatric patients with Behçet disease and to compare them with adult BD patients and healthy pediatric controls. The study focuses on the identification of disease-associated cytokine patterns, circulating microRNA profiles, DNA methylation signatures, and genetic variants associated with monogenic autoinflammatory diseases presenting with a Behçet-like phenotype. By integrating clinical data with multi-omic analyses, this study seeks to identify biologically and clinically meaningful patient subgroups, improve disease stratification, and explore potential biomarkers of disease activity and remission in pediatric Behçet disease.

Participants needed: 90
Trial details
Age: 6-70Biological sex: AllType: InterventionalSponsor: Meyer Children's Hospital IRCCSUpdated: Jan 29, 2026Locations: 2
Eligibility criteria

BD diagnosis according to at least one of the three sets of classification crite... [+2]

Patients who do not meet the BD criteria OR [+12]

Status: Not yet recruiting

Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease

This study is a Phase III, multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial investigating the treatment of lower extremity venous thrombosis associated with Behçet's Disease. The study compares the effectiveness and safety of immunosuppressive therapy alone versus immunosuppressive therapy combined with oral anticoagulation (Rivaroxaban).

Participants needed: 110
Trial details
Phase: Phase 3Age: 18-50Biological sex: AllType: InterventionalSponsor: Marmara UniversityUpdated: Apr 13, 2025Locations: 2
Eligibility criteria

Not listed